Corticosteroids and pulmonary rehabilitation reducing long-term morbidity in a patient with post-COVID-19 pneumonitis: A case study

Physiother Res Int. 2021 Jul;26(3):e1903. doi: 10.1002/pri.1903. Epub 2021 Mar 13.

Abstract

Background: Whilst research efforts have focussed on treatment during the acute phase, little work has focussed on the long-term sequelae of COVID-19 infection. This case described a patient who remained symptomatic several weeks after discharge from hospital with what was diagnosed as a COVID-19 infection. There were significant deficits shown in his functional exercise testing, his pulmonary functions testing and there was evidence of fibrotic changes on his radiology.

Methods: As part of a multidisciplinary clinic, he was started on steroids and a tailored pulmonary rehabilitation course over a course of 6-8 weeks. Thereafter, his exercise testing, pulmonary function tests and radiology were all repeated to see progress.

Results: On completing the course of corticosteroids and concurrent personalised pulmonary rehabilitation, there was a dramatic improvement in the patient's symptom severity, radiology and pulmonary function. The most significant improvement noted was in his exercise testing, namely a 6-min walk test and 1 min of sit-to-stands. Before treatment, he had a Medical Reserch Council (MRC) score of 2, and after it returned to his baseline of 0.

Discussion: Using corticosteroids and exercise training that allowed quantitative evaluation throughout the stages of recovery was a valuable tool to gauge progress and response to treatment. These therapies present opportunity to prevent the development of irreversible pulmonary fibrosis that could prove to be a major breakthrough in reducing long-term morbidity and improving the quality of life of those affected.

Keywords: breathlessness; physiotherapy; pulmonary rehabilitation; rehabilitation services.

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • COVID-19*
  • Humans
  • Male
  • Morbidity
  • Pneumonia* / drug therapy
  • Quality of Life
  • SARS-CoV-2

Substances

  • Adrenal Cortex Hormones